CSPC Pharmaceutical Group Limited et al. vs Ipsen Biopharm Ltd. et al.

Decision Granting Institution of Inter Partes Review

Scheduling Order

Petitioners' Updated Mandatory Notices Pursuant to 37 C.F.R. § 42.8(b)

Director Discretionary Decision: Refer

Ex. 3101

Petitioners' Response to Patent Owner's Request for Discretionary Denial of Institution

Supplemental Expert Declaration of Mark J. Ratain, MD

Chung, et al., Journal of Clinical Oncology, 43(17 suppl): LBA4175 (2025)

Chung, et al., NAPOLI 3 Phase 3 Trial of NALIRIFOX

Rochefort, et al., The Oncologist, 24:1543-1548 (2019)

Translation Certification of the English Translation of Conroy Protocol (Ex. 1004)

U.S. Patent No. 9,492,442

NCCN Clinical Practice Guidelines for Pancreatic Adenocarcinoma published on February 3, 2025.

Patel, et al., Journal of Clinical Oncology, 43(4 suppl):716 (2025)

Patent Owner's Discretionary Denial Brief

Ex. 2001

Ex. 2002

Ex. 2003

Ex. 2004

Ex. 2005

Ex. 2006

Ex. 2007

Ex. 2008

Ex. 2009

Ex. 2010

Ex. 2011

Ex. 2012

Ex. 2013

Patent Owner's Preliminary Response

Ex. 2014

Ex. 2015

Ex. 2016

Ex. 2017

Ex. 2018

Ex. 2019

Ex. 2020

Ex. 2021

Ex. 2022

Ex. 2023

Ex. 2024

Ex. 2025

Ex. 2026

Ex. 2027

Ex. 2028

Ex. 2029

Ex. 2030

Ex. 2031

Ex. 2032

Ex. 2033

Ex. 2034

Ex. 2035

NOTICE Extending Deadline for Discretion Briefing

Corrected Certificate of Service

Notice: Notice filing date accorded

Notice: Power of Attorney

Notice: Mandatory Notice

U.S. Patent No. 11,344,552 to Bayever et al. ("the '552 patent")

Conroy, et al., N. Engl. J. Med., 364(19):1817-25 (2011) (“Conroy”)

Certified English Translation of the Protocol of Conroy, et al.

Mahaseth, et al., Pancreas, 42(8):1311-15 (2013) (“Mahaseth”)

International Publication No. WO2013/188586 A1 to Bayever (“Bayever”)

Saif, Journal of the Pancreas, 15(3):278-79 (2014) (“Saif”)

Ko, et al., British J. of Cancer, 109(4):920-25 (2013) (“Ko”)

Cantore, et al., Oncology, 67(2):93-97 (2004) (“Cantore”)

Nichetti, et al., JAMA Network Open, 7(1):1-13 (2024) (“Nichetti”)

Nevala-Plagemann and Garrido-Laguna, Nature Reviews Clinical Oncology

Masi, et al., Annals of Oncology, 15:1766-72 (2004) (“Masi”)

Carnevale and Ko, Future Oncology, 12(4):453-464 (2016) (“Carnevale”)

Dean, et al., J Clin Oncol, 34(4 Suppl.):tps482 (2016) (“Dean”)

U.S. Provisional Application No. 62/208,209 to Bayever et al.

Ginocchi, et al., Annals of Oncology, 23(9 Suppl.):ix238 (2012) (“Ginocchi”

Conroy Supplementary Appendix, N. Engl. J. Med. (“Conroy Appendix”)

Wainberg, et al., Ann Oncol., 3l (Suppl. 3):S241 (2020)

Wainberg, et al., European Journal of Cancer, 151:14-24 (2021)

U.S. Non-Provisional Patent Application No. 15/241,106 to Bayever, et al.

Hatachi, et al., Cancer Diagn & Progn, 2(1):101-06 (2022)

Zaniboni, et al., Cancer Chemother Pharmacol., 69(6):1641-45 (2012)

Tsai, et al., J Gastrointest Oncol., 2(3):185-94 (2011)

U.S. Patent No. 8,147,867 to Hong, et al (“the ’867 patent”)

Press Release by Merrimack Pharmaceuticals, Inc. on August 1, 2011

International Publication No. WO 2016/094402 A1 to Bayever (“Bayever II”)

Alcindor, et al., Curr Oncol, 18(1):18-25 (2011)

U.S. Provisional Application No. 62/216,736 to Bayever et al.

U.S. Provisional Application No. 62/273,244 to Bayever et al.

U.S. Provisional Application No. 62/281,473 to Bayever et al.

U.S. Provisional Application No. 62/302,341 to Bayever et al.

U.S. Provisional Application No. 62/323,245 to Bayever et al.

Leucovorin Calcium Injection Label (2011)

Gemcitabine Injection Label (2012)

Abraxane Paclitaxel Label (2013)

XELODA Capecitabine Label (2000)

Camptosar FDA Label (2006)

Eloxatin Oxaliplatin Injection Label (2012)

Tarceva Erlotinib Tablets Label (2013)

Fluorouracil Injection Label (2012)

Conroy, et al., Curr Oncol Rep., 15(2):182-9 (2013)

Ko, J Clin Oncol, 29(28):3727–29 (2011)

Blazer, et al., ASCO Meeting Abstr. 32(Suppl. 3):275 (2014)

Alessandretti, et al., ASCO Meeting Abstr. 31 (Suppl. 15): e15176 (2013)

Paller, et al., Clin Cancer Res., 20(16); 4210–17 (2014)

Hamberg, et al., Eur J Cancer, 46(16):2870-78 (2010)

Hess, et al., Annals of Oncology, 21(12):2390-95 (2010)

Goel, et al., Anti-Cancer Drugs, 18(3):263-71 (2007)

Rachamalla, et al., Anticancer Drugs, 15(3):211-7 (2004)

Wildiers, Eur J Cancer, 43(15):2235-41 (2007)

Gajra, et al., J Geriatr Oncol, 6(2):133-40 (2015)

Shayne, et al., Cancer, 110(7):1611-20 (2007)

Sharma, et al., J Clinical Oncology, 32(3 Suppl.): 562 (2014)

Chang, et al., Cancer Chemother Pharmacol., 75(3):579-86 (2015)

Roy, et al., Annals of Oncology, 24(6):1567-73 (2013)

Slingerland, et al., Drug Discov Today, 17(3-4):160-66 (2012)

Chen, et al., J Clin Oncol, 26(15 Suppl.):2565 (2008)

Kim, et al., Cancer Res., 72(14 Suppl.): A41 (2012)

Hann, et al., Cancer Res, 67(9 Suppl.): 5648 (2007)

U.S. Non-Provisional Patent Application No. 62/343,313 to Bayever et al.

File History of U.S. Patent No. 11,344,552 Part 1 of 40

File History of U.S. Patent No. 11,344,552 Part 2 of 40

File History of U.S. Patent No. 11,344,552 Part 3 of 40

File History of U.S. Patent No. 11,344,552 Part 4 of 40

File History of U.S. Patent No. 11,344,552 Part 5 of 40

File History of U.S. Patent No. 11,344,552 Part 6 of 40

File History of U.S. Patent No. 11,344,552 Part 7 of 40

File History of U.S. Patent No. 11,344,552 Part 8 of 40

File History of U.S. Patent No. 11,344,552 Part 9 of 40

File History of U.S. Patent No. 11,344,552 Part 10 of 40

File History of U.S. Patent No. 11,344,552 Part 11 of 40

File History of U.S. Patent No. 11,344,552 Part 12 of 40

File History of U.S. Patent No. 11,344,552 Part 13 of 40

File History of U.S. Patent No. 11,344,552 Part 14 of 40

File History of U.S. Patent No. 11,344,552 Part 15 of 40

File History of U.S. Patent No. 11,344,552 Part 16 of 40

File History of U.S. Patent No. 11,344,552 Part 17 of 40

File History of U.S. Patent No. 11,344,552 Part 18 of 40

File History of U.S. Patent No. 11,344,552 Part 19 of 40

File History of U.S. Patent No. 11,344,552 Part 20 of 40

File History of U.S. Patent No. 11,344,552 Part 21 of 40

File History of U.S. Patent No. 11,344,552 Part 22 of 40

File History of U.S. Patent No. 11,344,552 Part 23 of 40

File History of U.S. Patent No. 11,344,552 Part 24 of 40

File History of U.S. Patent No. 11,344,552 Part 25 of 40

File History of U.S. Patent No. 11,344,552 Part 26 of 40

File History of U.S. Patent No. 11,344,552 Part 27 of 40

File History of U.S. Patent No. 11,344,552 Part 28 of 40

File History of U.S. Patent No. 11,344,552 Part 29 of 40

File History of U.S. Patent No. 11,344,552 Part 30 of 40

File History of U.S. Patent No. 11,344,552 Part 31 of 40

File History of U.S. Patent No. 11,344,552 Part 32 of 40

File History of U.S. Patent No. 11,344,552 Part 33 of 40

File History of U.S. Patent No. 11,344,552 Part 34 of 40

File History of U.S. Patent No. 11,344,552 Part 35 of 40

File History of U.S. Patent No. 11,344,552 Part 36 of 40

File History of U.S. Patent No. 11,344,552 Part 37 of 40

File History of U.S. Patent No. 11,344,552 Part 38 of 40

File History of U.S. Patent No. 11,344,552 Part 39 of 40

File History of U.S. Patent No. 11,344,552 Part 40 of 40

National Cancer Institute, "FDA Approves Irinotecan Liposome..." (2015)

Declaration of Dr. Mark Retain

Petition: as filed

Notice: Power of Attorney